Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7dbb98bdfa1646aab64644807868380f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7dbb98bdfa1646aab64644807868380f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7dbb98bdfa1646aab64644807868380f2021-12-02T19:47:33ZGut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction10.1128/mSystems.00188-172379-5077https://doaj.org/article/7dbb98bdfa1646aab64644807868380f2018-02-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSystems.00188-17https://doaj.org/toc/2379-5077ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.Youlian ZhouZhenjiang Zech XuYan HeYunsheng YangLe LiuQianyun LinYuqiang NieMingsong LiFachao ZhiSide LiuAmnon AmirAntonio GonzálezAnupriya TripathiMinhu ChenGary D. WuRob KnightHongwei ZhouYe ChenAmerican Society for Microbiologyarticlegut microbiotainfliximab treatmentdisease activityinflammatory bowel diseaseMicrobiologyQR1-502ENmSystems, Vol 3, Iss 1 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
gut microbiota infliximab treatment disease activity inflammatory bowel disease Microbiology QR1-502 |
| spellingShingle |
gut microbiota infliximab treatment disease activity inflammatory bowel disease Microbiology QR1-502 Youlian Zhou Zhenjiang Zech Xu Yan He Yunsheng Yang Le Liu Qianyun Lin Yuqiang Nie Mingsong Li Fachao Zhi Side Liu Amnon Amir Antonio González Anupriya Tripathi Minhu Chen Gary D. Wu Rob Knight Hongwei Zhou Ye Chen Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| description |
ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. |
| format |
article |
| author |
Youlian Zhou Zhenjiang Zech Xu Yan He Yunsheng Yang Le Liu Qianyun Lin Yuqiang Nie Mingsong Li Fachao Zhi Side Liu Amnon Amir Antonio González Anupriya Tripathi Minhu Chen Gary D. Wu Rob Knight Hongwei Zhou Ye Chen |
| author_facet |
Youlian Zhou Zhenjiang Zech Xu Yan He Yunsheng Yang Le Liu Qianyun Lin Yuqiang Nie Mingsong Li Fachao Zhi Side Liu Amnon Amir Antonio González Anupriya Tripathi Minhu Chen Gary D. Wu Rob Knight Hongwei Zhou Ye Chen |
| author_sort |
Youlian Zhou |
| title |
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| title_short |
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| title_full |
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| title_fullStr |
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| title_full_unstemmed |
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction |
| title_sort |
gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction |
| publisher |
American Society for Microbiology |
| publishDate |
2018 |
| url |
https://doaj.org/article/7dbb98bdfa1646aab64644807868380f |
| work_keys_str_mv |
AT youlianzhou gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT zhenjiangzechxu gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT yanhe gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT yunshengyang gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT leliu gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT qianyunlin gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT yuqiangnie gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT mingsongli gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT fachaozhi gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT sideliu gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT amnonamir gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT antoniogonzalez gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT anupriyatripathi gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT minhuchen gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT garydwu gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT robknight gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT hongweizhou gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction AT yechen gutmicrobiotaoffersuniversalbiomarkersacrossethnicityininflammatoryboweldiseasediagnosisandinfliximabresponseprediction |
| _version_ |
1718375969116389376 |